Seizure activity triggers tau hyperphosphorylation and amyloidogenic pathways.
amyloid
epileptogenesis
neurodegeneration
neuroinflammation
status epilepticus
tau phosphorylation
temporal lobe epilepsy
Journal
Epilepsia
ISSN: 1528-1167
Titre abrégé: Epilepsia
Pays: United States
ID NLM: 2983306R
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
revised:
31
01
2022
received:
26
11
2021
accepted:
31
01
2022
pubmed:
1
3
2022
medline:
14
4
2022
entrez:
28
2
2022
Statut:
ppublish
Résumé
Although epilepsies and neurodegenerative disorders show pathophysiological similarities, their direct functional associations are unclear. Here, we tested the hypothesis that experimental seizures can induce tau hyperphosphorylation and amyloidogenic modifications over time, with intersections with neuroinflammation. We used a model of mesial temporal lobe epilepsy (MTLE) where unilateral intrahippocampal injection of kainic acid (KA) in C57BL/6 mice elicits epileptogenesis and spontaneous focal seizures. We used a model of generalized status epilepticus (SE) obtained by intraperitoneal KA injection in C57BL/6 mice. We performed analyses and cross-comparisons according to a schedule of 72 h, 1 week, and 8 weeks after KA injection. In experimental MTLE, we show AT100, PHF1, and CP13 tau hyperphosphorylation during epileptogenesis (72 h-1 week) and long-term (8 weeks) during spontaneous seizures in the ipsilateral hippocampi, the epileptogenic zone. These pathological modifications extended to the contralateral hippocampus, a seizure propagating zone with no histological lesion or sclerosis. Two kinases, Cdk5 and GSK3β, implicated in the pathological phosphorylation of tau, were activated. In this MTLE model, the induction of the amyloidogenic pathway (APP, C99, BACE1) was prominent and long-lasting in the epileptogenic zone. These Alzheimer's disease (AD)-relevant markers, established during seizure progression and recurrence, reciprocated an enduring glial (GFAP, Iba1) inflammation and the inadequate activation of the endogenous, anti-inflammatory, glucocorticoid receptor system. By contrast, a generalized SE episode provoked a predominantly transient induction of tau hyperphosphorylation and amyloidogenic markers in the hippocampus, along with resolving inflammation. Finally, we identified overlapping profiles of long-term hippocampal tau hyperphosphorylation by comparing MTLE to J20 mice, the latter a model relevant to AD. MTLE and a generalized SE prompt persistent and varying tau hyperphosphorylation or amyloidogenic modifications in the hippocampus. In MTLE, an AD-relevant molecular trajectory intertwines with neuroinflammation, spatiotemporally involving epileptogenic and nonlesional seizure propagating zones.
Substances chimiques
Amyloid Precursor Protein Secretases
EC 3.4.-
Aspartic Acid Endopeptidases
EC 3.4.23.-
Kainic Acid
SIV03811UC
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
919-935Informations de copyright
© 2022 International League Against Epilepsy.
Références
Gourmaud S, Shou H, Irwin DJ, Sansalone K, Jacobs LM, Lucas TH, et al. Alzheimer-like amyloid and tau alterations associated with cognitive deficit in temporal lobe epilepsy. Brain. 2020;143:191-209.
Tai XY, Koepp M, Duncan JS, Fox N, Thompson P, Baxendale S, et al. Hyperphosphorylated tau in patients with refractory epilepsy correlates with cognitive decline: a study of temporal lobe resections. Brain. 2016;139:2441-55.
Casillas-Espinosa PM, Ali I, O'Brien TJ. Neurodegenerative pathways as targets for acquired epilepsy therapy development. Epilepsia Open. 2020;5:138-54.
Romoli M, Sen A, Parnetti L, Calabresi P, Costa C. Amyloid-beta: a potential link between epilepsy and cognitive decline. Nat Rev Neurol. 2021;17:469-85.
Silva JC, Vivash L, Malpas CB, Hao Y, McLean C, Chen Z, et al. Low prevalence of amyloid and tau pathology in drug-resistant temporal lobe epilepsy. Epilepsia. 2021;62(12):3058-67.
Joutsa J, Rinne JO, Hermann B, Karrasch M, Anttinen A, Shinnar S, et al. Association between childhood-onset epilepsy and amyloid burden 5 decades later. JAMA Neurol. 2017;74:583-90.
Gan L, Cookson MR, Petrucelli L, La Spada AR. Converging pathways in neurodegeneration, from genetics to mechanisms. Nat Neurosci. 2018;21:1300-9.
Boux F, Forbes F, Collomb N, Zub E, Mazière L, Bock F, et al. Neurovascular multiparametric MRI defines epileptogenic and seizure propagation regions in experimental mesiotemporal lobe epilepsy. Epilepsia. 2021;62(5):1244-55.
Klement W, Blaquiere M, Zub E, deBock F, Boux F, Barbier E, et al. A pericyte-glia scarring develops at the leaky capillaries in the hippocampus during seizure activity. Epilepsia. 2019;60:1399-411.
Klement W, Garbelli R, Zub E, Rossini L, Tassi L, Girard B, et al. Seizure progression and inflammatory mediators promote pericytosis and pericyte-microglia clustering at the cerebrovasculature. Neurobiol Dis. 2018;113:70-81.
Zub E, Canet G, Garbelli R, Blaquiere M, Rossini L, Pastori C, et al. The GR-ANXA1 pathway is a pathological player and a candidate target in epilepsy. FASEB J. 2019;33:13998-4009.
Runtz L, Girard B, Toussenot M, Espallergues J, Fayd'Herbe De Maudave A, Milman A, et al. Hepatic and hippocampal cytochrome P450 enzyme overexpression during spontaneous recurrent seizures. Epilepsia. 2018;59:123-34.
Rusina E, Bernard C, Williamson A. The kainic acid models of temporal lobe epilepsy. eNeuro. 2021;8(2):ENEURO.0337-20.2021.
Riban V, Bouilleret V, Pham-Le BT, Fritschy JM, Marescaux C, Depaulis A. Evolution of hippocampal epileptic activity during the development of hippocampal sclerosis in a mouse model of temporal lobe epilepsy. Neuroscience. 2002;112:101-11.
Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, et al. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci. 2000;20:4050-8.
Canet G, Zussy C, Hernandez C, Chevallier N, Marchi N, Desrumaux C, et al. Chronic glucocorticoids consumption triggers and worsens experimental Alzheimer's disease-like pathology by detrimental immune-modulations. Neuroendocrinology. 2022. https://doi.org/10.1159/000521559
Planel E, Richter KEG, Nolan CE, Finley JE, Liu L, Wen Y, et al. Anesthesia leads to tau hyperphosphorylation through inhibition of phosphatase activity by hypothermia. J Neurosci. 2007;27:3090-7.
Mansuy M, Baille S, Canet G, Borie A, Cohen-Solal C, Vignes M, et al. Deletion of plasma phospholipid transfer protein (PLTP) increases microglial phagocytosis and reduces cerebral amyloid-beta deposition in the J20 mouse model of Alzheimer's disease. Oncotarget. 2018;9:19688-703.
O'Leary TP, Savoie V, Brown RE. Learning, memory and search strategies of inbred mouse strains with different visual abilities in the Barnes maze. Behav Brain Res. 2011;216:531-42.
Canet G, Chevallier N, Zussy C, Desrumaux C, Givalois L. Central role of glucocorticoid receptors in Alzheimer's disease and depression. Front Neurosci. 2018;12:739.
Pineau F, Canet G, Desrumaux C, Hunt H, Chevallier N, Ollivier M, et al. New selective glucocorticoid receptor modulators reverse amyloid-beta peptide-induced hippocampus toxicity. Neurobiol Aging. 2016;45:109-22.
Zussy C, Brureau A, Keller E, Marchal S, Blayo C, Delair B, et al. Alzheimer's disease related markers, cellular toxicity and behavioral deficits induced six weeks after oligomeric amyloid-beta peptide injection in rats. PLoS One. 2013;8:e53117.
Canet G, Pineau F, Zussy C, Hernandez C, Hunt H, Chevallier N, et al. Glucocorticoid receptors signaling impairment potentiates amyloid-beta oligomers-induced pathology in an acute model of Alzheimer's disease. FASEB J. 2020;34:1150-68.
Andorfer C, Kress Y, Espinoza M, De Silva R, Tucker KL, Barde Y-A, et al. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem. 2003;86:582-90.
Sculier C, Gainza-Lein M, Sanchez Fernandez I, Loddenkemper T. Long-term outcomes of status epilepticus: a critical assessment. Epilepsia. 2018;59(Suppl 2):155-69.
Neely CLC, Pedemonte KA, Boggs KN, Flinn JM. Nest building behavior as an early indicator of behavioral deficits in mice. J Vis Exp. 2019;152(e60139):1-8. https://doi.org/10.3791/60139
Arango-Lievano M, Boussadia B, De Terdonck LDT, Gault C, Fontanaud P, Lafont C, et al. Topographic reorganization of cerebrovascular mural cells under seizure conditions. Cell Rep. 2018;23:1045-59.
Tan SH, Karri V, Tay NWR, Chang KH, Ah HY, Ng PQ, et al. Emerging pathways to neurodegeneration: dissecting the critical molecular mechanisms in Alzheimer's disease, Parkinson's disease. Biomed Pharmacother. 2019;111:765-77.
Vaillant-Beuchot L, Mary A, Pardossi-Piquard R, Bourgeois A, Lauritzen I, Eysert F, et al. Accumulation of amyloid precursor protein C-terminal fragments triggers mitochondrial structure, function, and mitophagy defects in Alzheimer's disease models and human brains. Acta Neuropathol. 2021;141:39-65.
Vezzani A, Balosso S, Ravizza T. Neuroinflammatory pathways as treatment targets and biomarkers in epilepsy. Nat Rev Neurol. 2019;15:459-72.
Minjarez B, Camarena HO, Haramati J, Rodríguez-Yañez Y, Mena-Munguía S, Buriticá J, et al. Behavioral changes in models of chemoconvulsant-induced epilepsy: a review. Neurosci Biobehav Rev. 2017;83:373-80.
Rattka M, Brandt C, Loscher W. The intrahippocampal kainate model of temporal lobe epilepsy revisited: epileptogenesis, behavioral and cognitive alterations, pharmacological response, and hippoccampal damage in epileptic rats. Epilepsy Res. 2013;103:135-52.
Monti G, Tondelli M, Giovannini G, Bedin R, Nichelli PF, Trenti T, et al. Cerebrospinal fluid tau proteins in status epilepticus. Epilepsy Behav. 2015;49:150-4.
Shahim P, Rejdak R, Ksiazek P, Blennow K, Zetterberg H, Mattsson N, et al. Cerebrospinal fluid biomarkers of beta-amyloid metabolism and neuronal damage in epileptic seizures. Eur J Neurol. 2014;21:486-91.
Sweeney MD, Kisler K, Montagne A, Toga AW, Zlokovic BV. The role of brain vasculature in neurodegenerative disorders. Nat Neurosci. 2018;21:1318-31.
Wu JW, Hussaini SA, Bastille IM, Rodriguez GA, Mrejeru A, Rilett K, et al. Neuronal activity enhances tau propagation and tau pathology in vivo. Nat Neurosci. 2016;19:1085-92.
Ascoli M, Ferlazzo E, Gasparini S, Mastroianni G, Citraro R, Roberti R, et al. Epidemiology and outcomes of status epilepticus. Int J Gen Med. 2021;14:2965-73.
Horvath L, Fekete I, Molnar M, Valoczy R, Marton S, Fekete K. The outcome of status epilepticus and long-term follow-up. Front Neurol. 2019;10:427.
Yan X-X, Cai Y, Zhang X-M, Luo X-G, Cai H, Rose GM, et al. BACE1 elevation is associated with aberrant limbic axonal sprouting in epileptic CD1 mice. Exp Neurol. 2012;235:228-37.
Liang Z, Liu F, Iqbal K, Grundke-Iqbal I, Gong CX. Dysregulation of tau phosphorylation in mouse brain during excitotoxic damage. J Alzheimers Dis. 2009;17:531-9.
Kodam A, Ourdev D, Maulik M, Hariharakrishnan J, Banerjee M, Wang Y, et al. A role for astrocyte-derived amyloid beta peptides in the degeneration of neurons in an animal model of temporal lobe epilepsy. Brain Pathol. 2019;29:28-44.
Liu S-J, Zheng P, Wright DK, Dezsi G, Braine E, Nguyen T, et al. Sodium selenate retards epileptogenesis in acquired epilepsy models reversing changes in protein phosphatase 2A and hyperphosphorylated tau. Brain. 2016;139:1919-38.
Ramos-Cejudo J, Wisniewski T, Marmar C, Zetterberg H, Blennow K, de Leon MJ, et al. Traumatic brain injury and Alzheimer's disease: the cerebrovascular link. EBioMedicine. 2018;28:21-30.
Ichkova A, Rodriguez-Grande B, Zub E, Saudi A, Fournier M-L, Aussudre J, et al. Early cerebrovascular and long-term neurological modifications ensue following juvenile mild traumatic brain injury in male mice. Neurobiol Dis. 2020;141:104952.
Sen A, Jette N, Husain M, Sander JW. Epilepsy in older people. Lancet. 2020;395:735-48.
Meijer OC, Koorneef LL, Kroon J. Glucocorticoid receptor modulators. Ann Endocrinol. 2018;79:107-11.
Vandewalle J, Luypaert A, De Bosscher K, Libert C. Therapeutic mechanisms of glucocorticoids. Trends Endocrinol Metab. 2018;29:42-54.
Brureau A, Zussy C, Delair B, Ogier C, Ixart G, Maurice T, et al. Deregulation of hypothalamic-pituitary-adrenal axis functions in an Alzheimer's disease rat model. Neurobiol Aging. 2013;34:1426-39.
Van Bogaert T, Vandevyver S, Dejager L, Van Hauwermeiren F, Pinheiro I, Petta I, et al. Tumor necrosis factor inhibits glucocorticoid receptor function in mice: a strong signal toward lethal shock. J Biol Chem. 2011;286:26555-67.
Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol. 2011;335:2-13.
Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science. 2007;316:750-4.
Jones NC, Nguyen T, Corcoran NM, Velakoulis D, Chen T, Grundy R, et al. Targeting hyperphosphorylated tau with sodium selenate suppresses seizures in rodent models. Neurobiol Dis. 2012;45:897-901.
DeVos SL, Goncharoff DK, Chen G, Kebodeaux CS, Yamada K, Stewart FR, et al. Antisense reduction of tau in adult mice protects against seizures. J Neurosci. 2013;33:12887-97.